Randy Milby, CEO of Hillstream BioPharma HILS, was a guest on Benzinga’s All-Access.
Hillstream BioPharma is a biotechnology company developing a focused portfolio of therapeutic candidates targeting drug-resistant and devastating cancers. The company’s emerging immuno-oncology pipeline is led by HSB-3215.
The company recently teamed up with Minotaur Therapeutics to license one of its key technologies. The tech will allow Hillstream to create more targeted and efficient therapies and advance its drug pipeline more rapidly.
Watch here:
Featured photo by National Cancer Institute on Unsplash.
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
